First Time Loading...

Catalent Inc
NYSE:CTLT

Watchlist Manager
Catalent Inc Logo
Catalent Inc
NYSE:CTLT
Watchlist
Price: 57.91 USD -0.28%
Updated: Jul 12, 2024
Have any thoughts about
Catalent Inc?
Write Note

Intrinsic Value

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer healt... [ Read More ]

The intrinsic value of one CTLT stock under the Base Case scenario is 52.34 USD. Compared to the current market price of 57.91 USD, Catalent Inc is Overvalued by 10%.

Key Points:
CTLT Intrinsic Value
Base Case
52.34 USD
Overvaluation 10%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Catalent Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CTLT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Company reasserts full year guidance, bearing net loss
Earnings Call Summary

Company reasserts full year guidance, bearing net loss

The quarter saw a 4%-6% decline in net revenue at $982 million due to a $85 million decrease in COVID-19 related revenue, offset by growths of 11% and 5% in Biologics and PCH respectively. Adjusted EBITDA plummeted by 38% to $115 million, and the company recorded an adjusted net loss of $19 million. Despite this, fiscal '24 guidance remains unchanged, expecting net revenue between $4.3 billion to $4.5 billion (3% growth at midpoint), adjusted EBITDA from $680 million to $760 million, and adjusted net income ranging from $113 million to $175 million.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Catalent Inc

Current Assets 2.5B
Cash & Short-Term Investments 162m
Receivables 1.3B
Other Current Assets 1B
Non-Current Assets 7.4B
PP&E 3.7B
Intangibles 3.2B
Other Non-Current Assets 407m
Current Liabilities 1B
Accounts Payable 377m
Accrued Liabilities 320m
Other Current Liabilities 310m
Non-Current Liabilities 5.3B
Long-Term Debt 4.9B
Other Non-Current Liabilities 328m
Efficiency

Earnings Waterfall
Catalent Inc

Revenue
4.1B USD
Cost of Revenue
-3.4B USD
Gross Profit
784m USD
Operating Expenses
-1B USD
Operating Income
-253m USD
Other Expenses
-923m USD
Net Income
-1.2B USD

Free Cash Flow Analysis
Catalent Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CTLT Profitability Score
Profitability Due Diligence

Catalent Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Negative Operating Income
37/100
Profitability
Score

Catalent Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

CTLT Solvency Score
Solvency Due Diligence

Catalent Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average D/E
Low Altman Z-Score
31/100
Solvency
Score

Catalent Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CTLT Price Targets Summary
Catalent Inc

Wall Street analysts forecast CTLT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTLT is 59.47 USD with a low forecast of 42.42 USD and a high forecast of 66.68 USD.

Lowest
Price Target
42.42 USD
27% Downside
Average
Price Target
59.47 USD
3% Upside
Highest
Price Target
66.68 USD
15% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CTLT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CTLT Price
Catalent Inc

1M 1M
+4%
6M 6M
+17%
1Y 1Y
+25%
3Y 3Y
-49%
5Y 5Y
+8%
10Y 10Y
+190%
Annual Price Range
57.91
52w Low
32.18
52w High
59.82
Price Metrics
Average Annual Return 11.43%
Standard Deviation of Annual Returns 60.22%
Max Drawdown -78%
Shares Statistics
Market Capitalization 10.4B USD
Shares Outstanding 180 980 000
Percentage of Shares Shorted 6.09%

CTLT Return Decomposition
Main factors of price return

What is price return decomposition?

CTLT News

Other Videos

Last Important Events
Catalent Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Catalent Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Catalent Inc Logo
Catalent Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

10.4B USD

Dividend Yield

0%

Description

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 17,300 full-time employees. The company went IPO on 2014-07-31. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.

Contact

NEW JERSEY
Somerset
14 Schoolhouse Rd
+17325376200.0
https://www.catalent.com/

IPO

2014-07-31

Employees

17 300

Officers

President, CEO & Director
Mr. Alessandro Maselli
Group President of Pharma & Consumer Health Segment
Dr. Aristippos Gennadios Ph.D.
President, Division Head for BioProduct Delivery & Chief of Staff
Mr. Ricky Hopson
Executive Chairman of the Board
Mr. John J. Greisch M.B.A.
Senior VP & CFO
Mr. Matti M. Masanovich
VP & Chief Accounting Officer
Mr. Michael J. Hatzfeld Jr.
Show More
Senior VP & Chief Information Officer
Mr. Charles Lickfold
Vice President of Investor Relations
Mr. Paul Surdez
Senior VP, General Counsel, Chief Compliance Officer & Secretary
Mr. Joseph A. Ferraro J.D.
Senior Vice President of Strategy & Corporate Development
Mr. Michael J. Grippo
Show Less

See Also

Discover More
What is the Intrinsic Value of one CTLT stock?

The intrinsic value of one CTLT stock under the Base Case scenario is 52.34 USD.

Is CTLT stock undervalued or overvalued?

Compared to the current market price of 57.91 USD, Catalent Inc is Overvalued by 10%.